Overview

A Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Subjects With Chronic Hepatitis C Genotype 1

Status:
Completed
Trial end date:
2015-09-09
Target enrollment:
Participant gender:
Summary
To demonstrate the effectiveness of Daclatasvir (DCV) 3 Direct Acting Antivirals (DAA) fixed dose combination in Genotype 1 Chronic Hepatitis C subjects.
Phase:
Phase 3
Details
Lead Sponsor:
Bristol-Myers Squibb